ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
FBXO45 enhances cell viability and glycolysis in cervical cancer via DUSP2 ubiquitination-mediated ERK1/2 activation.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
F-box protein 45 (FBXO45) is implicated in tumorigenesis and progression. However, the functions and underlying mechanisms of FBXO45 in cervical cancer (CC) have not been elucidated. This study investigated the role of FBXO45 in the malignant progression of CC cells. Gene expression profiling interactive analysis, tissue microarrays, quantitative real-time PCR, and gene enrichment analysis confirmed the correlation between FBXO45 and CC. FBXO45-knockdown and FBXO45-overexpressing HeLa cells and Caski cells were utilized to evaluate cell viability, metabolic characteristics and protein expression via CCK-8, Seahorse assays, measurement of lactate production, and Western blotting (WB). A mouse xenograft model validated the effects of FBXO45 knockdown. Concurrently, FBXO45-dual specificity phosphatase 2 (DUSP2) interaction was investigated using co-immunoprecipitation and WB. Overexpression of FBXO45 in CC tissues and cell lines was observed. Functional studies revealed that FBXO45 promoted cell viability, glycolysis, and ERK1/2 activation. FBXO45 interacted with and ubiquitinated DUSP2, leading to ERK1/2 activation and enhanced glycolysis. Tissue microarrays and Spearman correlation analysis confirmed the negative correlation between FBXO45 and DUSP2 in CC tissues. In summary, our results suggest that FBXO45 enhances cell viability and glycolysis in CC via DUSP2 ubiquitination-mediated ERK1/2 activation. Our findings identify FBXO45 as a therapeutic target for CC, guiding the development of new drugs.
Indexed as
Identifiers
40637745What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.